Anhui's VBP includes OTC TCM, challenging CR Sanjiu's pricing autonomy. There are concerns about weight-loss drug market saturation. CM310 missing NRDL negotiation puts Keymed in a passive position.
What is covered in the Full Insight:
Introduction
CR Sanjiu and Anhui's VBP Policy
Novo Nordisk Performance and Weight-Loss Drug Market
Keymed Biosciences Analysis
Market Review and Risk Disclosure
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.